An arsenic oxoacid consisting of three hydroxy groups attached to a central arsenic atom.
Chemical ID:
MESH:C032793
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; Phloretin inhibits the reaction [Arsenic Trioxide results in increased expression of MAPK8 mRNA]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]
[IL24 protein co-treated with Arsenic Trioxide] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; Arsenic Trioxide promotes the reaction [puerarin results in increased expression of MAPK8 protein]; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; Dicumarol inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; indole-5-carboxamide promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; KIRA6 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; MAP2K4 gene mutant form inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; MAPK8 affects the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased phosphorylation of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK1 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in increased expression of PTEN protein]; MAPK9 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; SCIO-469 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; selonsertib inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]
